Baseline Galectin-3 in Patients with Breast Cancer Scheduled for Anthracycline Therapy: Associations with Cardiac Biomarkers, Left Ventricular Function, and HFA-ICOS Risk Stratification
International Journal of Molecular Sciences · 09.11.2026 · 27 (21) · 10020
DOI: 10.3390/ijms272110020 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.11.2026. Verfasst von Anna Borowiec und 9 weiteren Autor:innen. Beteiligte Einrichtung: Non-Commercial Clinical Research Outpatient Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Hauptthemen laut MEDLINE: Breast Neoplasms, Anthracyclines, Galectin 3, Ventricular Function, Left. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Agency of Poland, Medical Research Agency.
Abstract (Originalsprache)
The clinical role of galectin-3 (Gal-3) as a biomarker in cardio-oncology remains uncertain. This study evaluated baseline Gal-3 concentrations and their associations with established cardiac biomarkers, left ventricular systolic function, and HFA-ICOS cardiovascular risk categories in patients with breast cancer before anthracycline-based chemotherapy. This cross-sectional baseline analysis included 103 patients enrolled in the EMPACT trial. Gal-3 concentrations were evaluated in relation to high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), HFA-ICOS risk categories, and clinical characteristics. Associations were assessed using Pearson correlation analyses and median regression. Mean baseline Gal-3 concentration was 6.3 ± 2.7 ng/mL. Gal-3 was positively correlated with hs-cTnT (r = 0.384, p < 0.001) and NT-proBNP (r = 0.278, p = 0.006), but not significantly correlated with LVEF or GLS. Gal-3 concentrations did not differ significantly across HFA-ICOS risk categories (p = 0.237). Patients aged ≥65 years had higher Gal-3 concentrations than younger patients (7.1 ± 2.8 vs. 5.7 ± 2.5 ng/mL, p = 0.003). In multivariable median regression, age was the only variable significantly associated with Gal-3 among the covariates included in the model (β = 0.82 ng/mL per 10-year increase, 95% CI 0.21–1.43, p = 0.009). Associations with hs-cTnT and NT-proBNP were no longer statistically significant after adjustment. In patients with breast cancer before anthracycline therapy, baseline Gal-3 concentrations were associated with age after multivariable adjustment, whereas associations with established cardiac biomarkers were attenuated. No significant associations were observed with LVEF or GLS, and Gal-3 concentrations did not differ significantly across HFA-ICOS risk categories in unadjusted analyses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Non-Commercial Clinical Research Outpatient Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Department of Cancer & Cardio-Oncology Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Unit for Screening Studies in Inherited Cardiovascular Diseases, The Cardinal Stefan Wyszynski National Institute of Cardiology, 04-628 Warsaw, Poland.
- Digital Medicine Center, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Cancer Biomarker and Cytokines Laboratory Unit, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Department of Brest Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
ORCID-Profile: Anna Borowiec, Nicola Maurea
Förderung
- Medical Research Agency of Poland
- Medical Research Agency
Zitieren
APA
Borowiec, A., Ozdowska, P., Zebrowska, A. M., Rosinska, M., Makowka, A., Puton, B., Pogoda, K., Nowecki, Z., Maurea, N., & Kotowicz, B. (2026). Baseline Galectin-3 in Patients with Breast Cancer Scheduled for Anthracycline Therapy: Associations with Cardiac Biomarkers, Left Ventricular Function, and HFA-ICOS Risk Stratification. International Journal of Molecular Sciences, 27(21), 10020. https://doi.org/10.3390/ijms272110020
Vancouver
Borowiec A, Ozdowska P, Zebrowska AM, Rosinska M, Makowka A, Puton B, et al. Baseline Galectin-3 in Patients with Breast Cancer Scheduled for Anthracycline Therapy: Associations with Cardiac Biomarkers, Left Ventricular Function, and HFA-ICOS Risk Stratification. International Journal of Molecular Sciences. 2026;27(21):10020. doi:10.3390/ijms272110020
BibTeX
@article{Borowiec2026,
author = {Borowiec, Anna and Ozdowska, Patrycja and Zebrowska, Agnieszka Maria and Rosinska, Magdalena and Makowka, Agata and Puton, Beata and Pogoda, Katarzyna and Nowecki, Zbigniew and Maurea, Nicola and Kotowicz, Beata},
title = {Baseline Galectin-3 in Patients with Breast Cancer Scheduled for Anthracycline Therapy: Associations with Cardiac Biomarkers, Left Ventricular Function, and HFA-ICOS Risk Stratification},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {10020},
doi = {10.3390/ijms272110020}
}
EUVIMED